Science Explorer Back to mapMap
Discussion
Researcher · Fujirebio (Belgium) · Belgium

Erik Depla

Erik Depla publishes mostly in Hepatology, Epidemiology and Immunology, on topics such as Hepatitis C virus research, Hepatitis B Virus Studies and Monoclonal and Polyclonal Antibodies Research.

ORCID 0009-0002-9232-4151 OpenAlex
World rank
#1,144,272
of 7,710,434 ranked researchers
Rank in Belgium
#10,475
of 67,186
Works
134
Citations
3.5k
Citations per work
25.9
h-index
25
i10-index 34Top 20% in Hepatology
Erik Depla

What does Erik Depla research?

Erik Depla's work is mostly in Medicine (58%), Immunology and Microbiology (12%), Biochemistry, Genetics and Molecular Biology (11%).

Health Sciences: 78 works · 57.9% of their workMedicine: 78 works · 57.9% of their workHepatology: 29 works · 21.3% of their workEpidemiology: 27 works · 20.3% of their workRadiology, Nuclear Medicine and Imaging: 15 works · 10.9% of their workRheumatology: 7 works · 5.4% of their workLife Sciences: 31 works · 22.8% of their workImmunology and Microbiology: 16 works · 11.9% of their workImmunology: 16 works · 11.9% of their workBiochemistry, Genetics and Molecular Biology: 15 works · 10.9% of their workMolecular Biology: 15 works · 10.9% of their workEverything else: 26 works · 19.3% of their workTHEIR WORKErik Depla134works
Life Sciences23%Health Sciences58%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine7857.9%
    1. Immunology and Microbiology1611.9%
    2. Biochemistry, Genetics and Molecular Biology1510.9%
  3. Everything else2619.3%
  1. 1Hepatology21% of their works
  2. 2Epidemiology20% of their works
  3. 3Immunology12% of their works
  4. 4Radiology, Nuclear Medicine and Imaging11% of their works
  5. 5Molecular Biology11% of their works
  6. 6Rheumatology5% of their works

Research topics

Which keywords describe Erik Depla's research?

The keywords of their largest research topics: Immune Response, Antiviral Therapy, Liver Disease, Hepatitis C Virus, Treatment, Chronic Hepatitis B, Hepatitis B Virus and Glycosylation.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Immune Response733 topics
  2. Antiviral Therapy682 topics
  3. Liver Disease682 topics
  4. Hepatitis C Virus381 topic
  5. Treatment381 topic
  6. Chronic Hepatitis B301 topic
  7. Hepatitis B Virus301 topic
  8. Glycosylation262 topics
  9. Fc Receptors211 topic
  10. Therapeutic Antibodies211 topic
  11. Antiphospholipid Syndrome111 topic
  12. Systemic Lupus Erythematosus111 topic
  13. Dendritic Cells61 topic
  14. Immunity61 topic
  15. Cancer51 topic
  16. Ebola Virus51 topic
  17. Foxp351 topic
  18. Glycans51 topic
  19. Outbreak51 topic
  20. TGF-ß51 topic

Where does Erik Depla work?

Erik Depla's main affiliation in the publication record is Fujirebio (Belgium), Belgium.

How many publications and citations does Erik Depla have?

OpenAlex counts 134 works and 3,469 citations for Erik Depla, an h-index of 25, ranking #1,144,272 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Erik Depla. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.